Dabigatran etexilate is an anticoagulant that also functions as a direct thrombin inhibitor. It is sold over the counter under a variety of brand names, including Pradaxa. The purpose of this article is to provide a comprehensive overview of dabigatran, including its indications, dosage and administration, side effects, and important considerations for use.

Listing of the ContentsSigns and Symptoms of UseMedications and their AdministrationOperation of the MechanismPharmacokinetics 

• Reactions between DrugsEffects That Are BadParticular Groups of PeopleThe monitoring and testing in the laboratorySigns and Symptoms of UseIndications for the use of dabigatran include the following conditions:Patients diagnosed with nonvalvular atrial fibrillation should be given medication to prevent stroke and systemic embolism

• Medications for the treatment of pulmonary embolism and deep vein thrombosisAfter receiving initial treatment, there is a decreased likelihood of recurrent deep vein thrombosis and pulmonary embolism having occurred

• Among the most important considerations is the fact that dabigatran pellets should not be administered to patients who have mechanical heart valves or renal impairment ranging from moderate to severe

• Medications and their AdministrationFor the majority of indications, the dosage of dabigatran that is recommended is 150 milligrams to be taken orally twice daily

• It is recommended that patients who are taking certain P-glycoprotein inhibitors or who have severe renal impairment take 75 milligrams twice daily instead of the standard dose

• It is recommended that dabigatran be taken concurrently with food, and that the capsules be swallowed in their entirety, without being opened or chewed

• Operation of the MechanismProdrug dabigatran etexilate is rapidly transformed into its active form, dabigatran pellets, by esterases in the liver

In addition, a rash and an increase in liver enzymes might appear. If there is a significant bleed, a bleed that threatens life, or bleeding that is not appropriate for continued treatment, the treatment should be discontinued. Particular Groups of PeopleIn cases of moderate to severe renal impairment or hemodialysis, this medication is not recommended. Patients who are elderly have a greater risk of bleeding. Data on lactation and pregnancy are quite limited. In the event that antiplatelet or anticoagulant bridging therapy is required for procedures, it should be considered. As far as monitoring and laboratory tests are concerned, routine coagulation monitoring is not required. If it is necessary for compliance, or in the event of bleeding or overdose, you might want to think about measuring the trough drug levels or the ecarin clotting time.